Is It Too Late To Consider Stryker (SYK) After Recent Share Price Strength?

Simply Wall St.

Feb 28

If you are wondering whether Stryker's share price around US$386 still offers value, you are not alone; many investors are trying to work out what a fair price looks like today. Over shorter periods, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614866105"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614866105\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614866105?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/94614-main-header/1756253509683","is_english":true,"pubTime":"2026-02-28 01:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614866105","market":"us","top_or_hot":-1,"title":"Is It Too Late To Consider Stryker (SYK) After Recent Share Price Strength?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Stryker's share price around US$386 still offers value, you are not alone; many investors are trying to work out what a fair price looks like today. Over shorter periods, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-share-pr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Stryker (SYK) After Recent Share Price Strength?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Stryker (SYK) After Recent Share Price Strength?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 01:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-share-pr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Stryker's share price around US$386 still offers value, you are not alone; many investors are trying to work out what a fair price looks like today. Over shorter periods, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-share-pr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-share-pr","article_id":"2614866105","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/94614-main-header/1756253509683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-share-pr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614866105","pubTimestamp":1772213959,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Stryker's share price around US$386 still offers value, you are not alone; many investors are trying to work out what a fair price looks like today.\nOver shorter periods, the stock has seen returns of 3.6% over the last 7 days, 8.9% over the last 30 days and 10.9% year to date, while the 1 year return sits at 0.2% and the 3 and 5 year returns are 51.6% and 72.4% respectively.\nRecent news coverage around Stryker has mainly centered on its position as a large...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4566":"资本集团","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4082":"医疗保健设备","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4504":"桥水持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SYK":"史赛克","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","BK4588":"碎股","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC"},"translate_title":"在最近股价走强之后，考虑史赛克（SYK）是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"SYK":1.5},"content_text":"If you are wondering whether Stryker's share price around US$386 still offers value, you are not alone; many investors are trying to work out what a fair price looks like today. Over shorter periods, the stock has seen returns of 3.6% over the last 7 days, 8.9% over the last 30 days and 10.9% year to date, while the 1 year return sits at 0.2% and the 3 and 5 year returns are 51.6% and 72.4% respectively. Recent news coverage around Stryker has mainly centered on its position as a large medical technology company and its role in key healthcare trends, which helps frame how investors think about its long term prospects. This context is important when you compare the recent share price performance with how the business is perceived in the market. Despite that background, Stryker currently has a valuation score of 0 out of 6. Next we will run through the usual valuation approaches and then finish with a broader way to think about what the current price really means for you.  Stryker scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Stryker Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today using an assumed required return. It is essentially asking what all those future dollars are worth in your hand right now. For Stryker, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $4.27b. Analyst estimates are available for several years, and Simply Wall St then extrapolates further to build a ten year path, which includes projected free cash flow of about $8.61b in 2035. Running these projections through the DCF model results in an estimated intrinsic value of about $357.86 per share, compared with the current price around $386. That implies the shares are about 7.9% above the modelled fair value, so the current market price is not far from what this method suggests. Result: ABOUT RIGHT Stryker is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act. SYK Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Stryker. Approach 2: Stryker Price vs Earnings For a profitable business like Stryker, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It links directly to the company’s bottom line, which is what ultimately supports shareholder returns over time. What counts as a “normal” P/E often reflects two big things: how quickly earnings are expected to change and how risky those earnings are perceived to be. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower multiple. Stryker currently trades on a P/E of 45.51x. That sits above the Medical Equipment industry average of 30.88x and also above the peer group average of 39.98x. Simply Wall St’s Fair Ratio for Stryker is 40.68x. This Fair Ratio is a proprietary estimate of what P/E might be reasonable given factors like Stryker’s earnings growth profile, industry, profit margins, market cap and specific risks. As a result, it can be more tailored than a simple comparison to peers or the broader industry. Since Stryker’s actual P/E of 45.51x is higher than the Fair Ratio of 40.68x, the shares screen as somewhat expensive on this metric. Result: OVERVALUED NYSE:SYK P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Stryker Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Narratives are simply your story about Stryker, linked to numbers like your assumed fair value and expectations for future revenue, earnings and margins. On Simply Wall St’s Community page you can easily connect the company’s story to a financial forecast, compare your fair value to the current price to help inform your decisions, and have that view update automatically as new news or earnings arrive. For example, you might see Stryker closer to a US$323 fair value based on your required return, or nearer to US$424 if you think the company can support higher growth and profitability. For Stryker however, we will make it really easy for you with previews of two leading Stryker Narratives: 🐂 Stryker Bull Case Fair value in this narrative: US$424.40 per share Implied discount to this fair value: about 9.1% below the narrative fair value, based on the recent price of US$386.06 Revenue growth assumption: 8.47% a year  The thesis leans on aging populations, chronic disease and minimally invasive procedures supporting ongoing procedure volumes across orthopedics, neurotechnology and related areas. It assumes continued benefits from international expansion, product approvals, robotics and digital health, alongside integration of acquisitions and margin improvement. It highlights risks from regulatory delays, supply chain issues, tariffs, pricing pressure and acquisition related costs that could weigh on margins and earnings if they do not break in Stryker's favor.  🐻 Stryker Bear Case Fair value in this narrative: US$323.52 per share Implied premium to this fair value: about 19.3% above the narrative fair value, based on the recent price of US$386.06 Revenue growth assumption: 6% a year  This narrative focuses on Stryker's solid balance sheet, with equity above debt and a lower net debt position once cash is considered. It frames the shares as roughly aligned with a DCF based fair value around US$323 using 6% annual return and discount rate assumptions, with future value tied to higher free cash flow and return on equity. It flags that execution over the next few years needs to support the projected free cash flow and earnings profile and notes that recent insider selling flagged by tools may not reflect management sentiment.  Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying! NYSE:SYK 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}